You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

43 search results for: chronic inflammation

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
expert video

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

Dermatology
This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
View more
Overview of Type 2 <b>Inflammation</b> in the Presentations of AD, PN, and CSU
expert video

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

Dermatology
Dr. Eric Simpson summarizes the role of type 2 inflammation in the clinical manifestations of AD, PN, and CSU.
View more
Itch: The Common Thread in Dermatological Type 2 <b>Inflammation</b> (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
Itch: The Common Thread in Dermatological Type 2 <b>Inflammation</b> (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
Type 2 <b>Inflammation</b> and Neuroimmune Axis Dysregulation in AD, PN, and CSU
expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

Dermatology
Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.
View more
Contribution of Type 2 Cytokines to <b>Inflammation</b> and Itch in AD, PN, and CSU 
expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 

Dermatology
Dr. Marta Ferrer describes the roles of type 2 cytokines in the processes involved in AD, PN, and CSU pathogenesis.
View more
How Does Protective Type 2 Immunity Become Harmful Type 2 <b>Inflammation</b>?
expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

Dermatology
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South AfricaChange country/region